Only 5% of all anti-cancer drug candidates earn approval; thus, oncology programs carry huge financial risks. At the root of most late stage failures is inefficient or poor transferability of preclinical results. What can you do to improve translation?
Learn how to facilitate your preclinical profiling with in vitro assays that use patient-derived material. Efficient and cost-effective, these assays accelerate model selection and help you effectively establish conditions for in vivo efficacy. Discover how scientists are using these in vitro/ev vivo models to optimize immuno-oncological approaches and see how live-cell imaging and multiplex analysis can help us understand treatment efficacy.
Claudia Göttlich, PhD
Study Director, In Vitro
We are providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.